Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ala’a Sharaf & Hashim Hashim. (2017) Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Design, Development and Therapy 11, pages 463-467.
Read now
Read now
Zalmai Hakimi, Jameel Nazir, Charles McCrea, Malin Berling, Francis Fatoye, Barbara Ramos & Adrian Wagg. (2017) Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada. Journal of Medical Economics 20:6, pages 614-622.
Read now
Read now
Articles from other publishers (14)
Emma Mitidieri, Annalisa Pecoraro, Erika Esposito, Vincenzo Brancaleone, Carlotta Turnaturi, Luigi Napolitano, Vincenzo Mirone, Ferdinando Fusco, Giuseppe Cirino, Raffaella Sorrentino, Giulia Russo, Annapina Russo & Roberta d’Emmanuele di Villa Bianca. (2022) β3 Relaxant Effect in Human Bladder Involves Cystathionine γ-Lyase-Derived Urothelial Hydrogen Sulfide. Antioxidants 11:8, pages 1480.
Crossref
Crossref
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Seok Ho Kang, Jun Cheon & Jeong Gu Lee. (2021) Effects of β3-adrenoceptor agonist on acute urinary retention in a rat model. World Journal of Urology 39:12, pages 4427-4433.
Crossref
Crossref
Elie El Helou, Chris Labaki, Roy Chebel, Jeanine El Helou, Georges Abi Tayeh, Georges Jalkh & Elie Nemr. (2019) The use of mirabegron in neurogenic bladder: a systematic review. World Journal of Urology 38:10, pages 2435-2442.
Crossref
Crossref
Pankaj Mandpe, Bala Prabhakar & Pravin Shende. (2020) Potential of Mirabegron and its Extended-release Formulations for the Treatment of Overactive Bladder Syndrome. Current Drug Metabolism 21:2, pages 79-88.
Crossref
Crossref
Lingdi Chen & Yu Zhang. (2019) Determination of Mirabegron in rat plasma by UPLC–MS/MS after oral and intravenous administration. Revista da Associação Médica Brasileira 65:2, pages 141-148.
Crossref
Crossref
Arcangelo Sebastianelli, Giorgio I Russo, Steven A Kaplan, Kevin T McVary, Ignacio Moncada, Stavros Gravas, Christopher Chapple, Giuseppe Morgia, Sergio Serni & Mauro Gacci. (2018) Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. International Journal of Urology 25:3, pages 196-205.
Crossref
Crossref
Jason C. Simeone, Beth L. Nordstrom, Kwame Appenteng, Samuel Huse & Milbhor D’Silva. (2017) Replication of Mini-Sentinel Study Assessing Mirabegron and Cardiovascular Risk in Non-Mini-Sentinel Databases. Drugs - Real World Outcomes 5:1, pages 25-34.
Crossref
Crossref
Takeharu Kaneda, Noriyasu Sasaki, Norimoto Urakawa & Kazumasa Shimizu. (2018) Effects of chlorogenic acid on carbachol-induced contraction of mouse urinary bladder. Journal of Pharmacological Sciences 136:1, pages 26-30.
Crossref
Crossref
Roxana Geoffrion. (2017) No 353 – Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie – Addenda. Journal of Obstetrics and Gynaecology Canada 39:12, pages 1230-1239.
Crossref
Crossref
Roxana Geoffrion. (2017) No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy – An Addendum. Journal of Obstetrics and Gynaecology Canada 39:12, pages 1221-1229.
Crossref
Crossref
Karl Erik Andersson. (2017) On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder. International Neurourology Journal 21:1, pages 6-11.
Crossref
Crossref
Linda Nazarko. (2017) Diabetes series, 6. Diabetes and bladder dysfunction. British Journal of Healthcare Assistants 11:3, pages 110-115.
Crossref
Crossref
Bronagh McDonnell & Lori Ann Birder. (2017) Recent advances in pharmacological management of urinary incontinence. F1000Research 6, pages 2148.
Crossref
Crossref
Linda Nazarko. (2016) A guide to lower urinary tract symptoms in women. Practice Nursing 27:7, pages 319-324.
Crossref
Crossref